Journal article
Combined effects of routine blood pressure lowering and intensive glucose control on macrovascular and microvascular outcomes in patients with type 2 diabetes: New results from the ADVANCE trial.
Sophia Zoungas, Bastiaan E de Galan, Toshiharu Ninomiya, Diederick Grobbee, Pavel Hamet, Simon Heller, Stephen MacMahon, Michel Marre, Bruce Neal, Anushka Patel, Mark Woodward, John Chalmers, undefined ADVANCE Collaborative Group, Alan Cass, Paul Glasziou, Stephen Harrap, Liu Lisheng, Guiseppe Mancia, Avinesh Pillai, Neil Poulter Show all
Diabetes Care | Published : 2009
DOI: 10.2337/dc09-0959
Abstract
OBJECTIVE: To assess the magnitude and independence of the effects of routine blood pressure lowering and intensive glucose control on clinical outcomes in patients with long-standing type 2 diabetes. RESEARCH DESIGN AND METHODS: This was a multicenter, factorial randomized trial of perindopril-indapamide versus placebo (double-blind comparison) and intensive glucose control with a gliclazide MR-based regimen (target A1C 0.1): the separate effects of the two interventions for the renal outcomes and death appeared to be additive on the log scale. Compared with neither intervention, combination treatment reduced the risk of new or worsening nephropathy by 33% (95% CI 12-50%, P = 0.005), new o..
View full abstract